Clinical Trials Logo

Filter by:
NCT ID: NCT06301373 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

Methotrexate Combined With Tofacitinib in Rheumatoid Arthritis

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

Rheumatoid arthritis (RA) is the leading cause of disability in Chinese women. We established a synovial pathology queue in the early stage and proposed a new synovial immunopathology classification. We found that baseline myeloid stromal RA patients had severe conditions and poor outcome. Early identification of synovial myeloid stromal RA patients and intensified treatment are key to improving RA efficacy. This project aims to conduct a randomized, controlled, open label, multicenter clinical study on early intensified treatment of RA based on synovial pathology classification. 130 adult patients with synovial myeloid stromal type of primary treatment moderate to severe active RA were planned to be enrolled in three centers: Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University; Shenshan Medical Center, Memorial Hospital of Sun Yat-Sen University, and Guangzhou Panyu Central Hospital. They were randomly divided into an intensive treatment group and a conventional treatment group in a 1:1 ratio. The intensive treatment group was treated with methotrexate combined with tofacitinib, while the conventional treatment group was treated with methotrexate monotherapy. The expected intervention period is 12 weeks, with a follow-up period of 48 weeks. The primary endpoint is the proportion of subjects who achieved ACR20 at week 12. Secondary endpoint indicators include improvement in disease activity and joint function among subjects at different follow-up points, safety, and the proportion of subjects who experienced joint destruction progression at week 48. This project proposes the concept of achieving precise diagnosis of RA based on synovial pathology classification, and explores the efficacy of early methotrexate combined with tofacitinib intensified treatment for patients with synovial medullary stromal RA who have poor conventional treatment efficacy, providing high-level clinical evidence for achieving precise initial treatment of RA treatment guidelines.

NCT ID: NCT06301386 Not yet recruiting - Colon Cancer Clinical Trials

Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients

Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to learn about efficacy of Everolimus in combination with PD-1 in patients with locally advanced and advanced colorectal cancer that cannot be R0 resected. The main question is to explore the survival time, safety and tolerability of the treatment. At the same time, the correlation between biomarkers (including PD-L1 expression, tumor mutation load, lymphocyte subpopulation, cytokines, TCR, intestinal microbes, and others) and the efficacy and drug resistance mechanism will be analyzed, so as to provide reference for the subsequent guidance of the screening of benefit groups.

NCT ID: NCT06301477 Not yet recruiting - Crohn Disease Clinical Trials

PRecisiOn Microbiome Directed ExtensiOn of Anti-TNFα Crohn's Disease ThErapy in Children: The PROMOTE Trial

PROMOTE
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

To determine whether a specific food-origin plant-derived resistant starch (RS) optimized for the individual will increase the abundance of known butyrate producing microbes.

NCT ID: NCT06302192 Not yet recruiting - Acute Kidney Injury Clinical Trials

Renal Doppler to Predict Acute Kidney Injury (AKI) in ARDS Patients. (RED-AKI Study)

RED-AKI
Start date: April 1, 2024
Phase:
Study type: Observational

This is a multicenter international observational prospective cohort study. The main questions it aims to answer are: - PRIMARY AIM: To describe the capability of IRVF demodulation at diagnosis of ARDS to predict development of AKI within 7 days from the ARDS onset - SECONDARY AIMS: A)Describe the capability of IRVF demodulation or pattern of IRVF (continuous, pulsatility, biphasic, monophasic) to predict development of AKI within 14 days from the ARDS onset. B) To describe the RD parameters and VexUS in the AKI and no AKI patients over time. C) Describe the impact of invasive mechanical ventilation (IMV) on the intrarenal venous congestion and VexUS., D) Evaluation of effect of CRRT on IRVF pattern, VexUS and parameters. E) Describe the feasibility of renal doppler to assess IRVF in critically ill respiratory patients. F) Evaluate the incidence of AKD and CKD Participants will Adult patients with diagnosis of ARDS admitted to intensive care unit and undergoing invasive mechanical ventilation

NCT ID: NCT06302218 Not yet recruiting - Knee Osteoarthritis Clinical Trials

ESPB vs iPACK+ACB in Total Knee Arthroplasty

Start date: April 1, 2024
Phase: Phase 4
Study type: Interventional

Effect of iPACK block with Adductor Canal Block and ESPB on pain management, and NLR and PLR following knee arthroplasty

NCT ID: NCT06302712 Not yet recruiting - Clinical trials for Obsessive-Compulsive Disorder

Traditional Islamically Integrated Psychotherapy for Muslims With OCD in Pakistan

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The current study aims to determine the effectiveness of the first culturally adapted Traditional Islamically Integrated Psychotherapy (TIIP) for Muslims with OCD in Pakistan along with the module effectiveness in reducing OCD symptoms with comorbidities like anxiety, depression, stress, thought control, thought-action fusion, and enhancing the spiritual quality of life of participants.

NCT ID: NCT06302803 Not yet recruiting - Obesity Clinical Trials

Modified Intermittent Eating on Weight Loss (INTEREST-3 Trial)

INTEREST-3
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

Calorie restriction (CR) is the most important treatment for weighting loss. In recent years, two novel types of intermittent fasting recently have gained more attention: the 5:2 diet and time-restricted eating (TRE). TRE requires individuals to eat in a specified number of hours per day (typically 4 to 10 hours) without energy intake restriction. The 5:2 diet involves 5 feast days and 2 fast days per week; participants eat ad libitum without restriction on feast days while 25% of energy needs (approximately 500-800 kcal per day) are consumed on fast days. However, the effects of dietary strategy of intermittent fasting plus time-restricted eating (modified time-restricted eating: TRE 5 days and fasting 2days per week) on weight loss and cardiometabolic risk factors in obese adults have not been proved. This randomized controlled trial aimed to evaluate the effect of modified time-restricted eating (mTRE) and CR on weight loss and cardiometabolic risk factors in obese adults compared to usual health care over 12 months.

NCT ID: NCT06303089 Not yet recruiting - Smoking Cessation Clinical Trials

Tobacco Exposure and Influencing Factors of Smoking Cessation Among Chronic Kidney Disease Patients

Start date: April 1, 2024
Phase:
Study type: Observational

The purpose of this study is to describe the tobacco exposure and characteristics of patients with Chronic Kidney Disease (CKD) who quit smoking, to identify patients' tobacco-related knowledge, attitude, and practice (KAP) and explore the influencing factors of smoking cessation.

NCT ID: NCT06304324 Not yet recruiting - Foot Diseases Clinical Trials

Dexmedetomidine vs Dexamethasone in Popliteal Nerve Block

Start date: April 1, 2024
Phase: Phase 4
Study type: Interventional

Effect of Perineural Dexmedetomidine vs. Dexamethasone on the duration of popliteal nerve block for Anesthesia After Pediatric ankle/foot surgery.

NCT ID: NCT06304415 Not yet recruiting - Clinical trials for Cardiovascular Diseases

Elevated Lipoprotein(a) in Hospital Staff

LPACO
Start date: April 1, 2024
Phase:
Study type: Observational [Patient Registry]

The objective of this study is to investigate the prevalence of elevated Lp(a) in the working general population.